Pediatric Drug Development: Concepts and Applications
Drawing from years of experience in pediatric medicine, Andrew Mulberg, Senior Director of Clinical Research & Development, Johnson and Johnson, LLC felt there was an unmet need for a textbook devoted to an understanding of the issues surrounding development of pharmaceutical-based therapies in pediatric drug development. As an outgrowth of this passion for pediatric medicine, he set out to complete the first comprehensive book detailing the concepts and applications of pediatric drug development.
Today, the product of his work and his passion has yielded his second publication, entitled, Pediatric Drug Development: Concepts and Applications published by Wiley Blackwell. Created in collaboration with Steve A. Silber, Vice President of Established Products at J&JPRD and John van den Anker, Professor of Pediatric Clinical Pharmacology, Children's National Medical Center, Washington, DC and many of his J&JPRD/academic/ government colleagues, Pediatric Drug Development: Concepts and Applications was designed as both a reference and a textbook.
The publication explores the scientific differences between the pediatric and the adult subject in the development of medicines, while taking into account the ethics and medical needs of pediatric patients. In addition, the book examines the overarching business case for the proper development of drugs for children, as well as the technical feasibility studies and processes that are necessary for a successful program. The book aims to provide the information necessary to ensure better and safer drugs for pediatric patients.
For more information on Pediatric Drug Development: Concepts and Applications, please click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
